Medication for treating clinical mastitis

FIELD: medicine.

SUBSTANCE: invention relates to veterinary, in particular to obstetrics, gynecology and reproduction biotechnology, and can be used for treating animals in case of clinical mastitis. Medication for treating animals with clinical mastitis includes: trivit - 10.0 ml, cefotaximum - 750 mg, prednisolone - 10.0 mg, nystatin - 325.0 ml. Medication is introduced to ill animals intracycternally in dose 10.0 ml with interval 12 hours after milking.

EFFECT: invention provides increased efficiency of treating clinical mastitis by complex impact on all sides of pathological process.

4 tbl, 3 ex

 

The invention relates to veterinary medicine, in particular to obstetrics, gynecology and biotechnology of reproduction. Can be used for treatment of animals with clinical mastitis.

Known drug septel. It includes iodopovidone and gel-forming base, polyoxethylene or glycerol, or citrate-Vostochny buffer (Century, Gavrish, A. I. Egunova, S. C., Semenov, S. C. Novikov. Septopal for treatment of cows with mastitis. J., veterinary science, 2000, No. 6, S. 33-36). The product is a gel red-brown color. Has a wide spectrum of antimicrobial action, the appropriate range of active iodine. It has anti-inflammatory and wound healing properties.

Disadvantage - you cannot type animals with hypersensitivity to iodine preparations.

Known drug drug Cobactan LC. As the active substance contains cefquinome sulfate and excipient - white soft paraffin, paraffin oil. The drug has a broad spectrum of bactericidal action against gram-positive and gram-negative aerobic and anaerobic bacteria. Resistant to penicillin (A. Oleinik. Cobaltic LC - a new drug for the treatment of mastitis. J., veterinary with. farm animals. 2010, No. 10, S. 33-34).

The disadvantage of this drug is that it has only antimicrobial effect, n is affecting the resistance of the tissues of the breast.

Known drug mastomatic. It consists of gentamicin sulfate, clindamycin hydrochloride, lidocaine hydrochloride (C. I. Sidorkin, C. A. Orobets. The use of matomela inflammation of the mammary gland in cows. J., veterinary medicine, 2007, No. 10, S. 35-37). The drug is administered internatinale in the dose of 10 ml with an interval of 12 hours after milking.

The disadvantage of this drug is that the sensitivity of microflora isolated from the mammary gland during mastitis, very low, and it cannot be used in combination with other drugs.

The aim of the invention is the creation of tools that improve the treatment of clinical mastitis by a complex influence on all aspects of the pathological process.

The proposed treatment for animals with clinical mastitis includes trivet, Cefotaxime, prednisolone, nystatin is in the following ratio:

trivet10.0 ml
Cefotaxime750 mg
prednisolone10.0 mg
nystatin325,0 ml

Trivet contains vitamins a, D, E, increases the resistance of the animal organism, accelerates the generacio secretory epithelium, lining the alveoli and milk ducts.

Cefotaxime is an antibiotic, cephalosporin, third generation broad-spectrum activity against gram-positive and gram-negative microorganisms.

Prednisolone is a drug, a hormone of the adrenal cortex, has anti-inflammatory and antiallergic action.

Nystatin is an antifungal antibiotic effect on pathogenic fungi and aspergilly.

The proposed treatment for clinical mastitis is prepared as follows: the required number of trivita placed in a porcelain Cup, to it add the specified number of Cefotaxime, prednisolone and nystatin and mix thoroughly to obtain a homogeneous mass.

The tool is administered to sick animals internatinale at a dose of 10.0 ml with an interval of 12 hours after milking.

Example 1. To determine the ratio of components in the treatment for clinical mastitis were made the means of two structures: part 1 - trivet - 10.0 ml, cefotaxim - 750 mg, prednisolone 5 mg, nystatin - 330 ml., part of the 2 - trivet - 10.0 ml, cefotaxim - 750 mg, prednisolone 10 mg, nystatin - 325 ml.

Cefotaxime has a strong antimicrobial action, trivet General-stimulating regenerative doses of these components are used according to the instructions and so they are permanent. For Copywrite drug that he possessed antifungal activity, introduced nystatin, anti-allergic - prednisone. The dose of the latter two components were determined experimentally.

From cows aged 4-7 years of red steppe breed, with signs of postpartum catarrhal-purulent mastitis formed 2 groups of 18 animals each, according to the principle of pairs of analogues. Cows first group was administered the drug in the composition is 1, the second group - part 2. The drugs were injected sick animals internatinale at a dose of 10.0 ml with an interval of 12 hours after the morning and evening milking to recovery. Was inventoried recovered cows, as well as the duration of their treatment.

Table 1 presents the results of therapeutic efficacy of a treatment for clinical mastitis.

/tr>
Table 1
Comparative efficacy of different formulations tools
GroupNThe timing of the improvements, the dayThe duration of therapeutic course, the dayRecovered
goals%
1184-57,418100
21836,218100

Improvement in patients of animals was noted in the second group, on the third day of drug administration in cows in the first group improvement occurred within 4-5 days. In the experimental animals were observed reduction of inflammatory edema, the number of catarrhal-purulent exudate. Recovery occurred in cows of group 2 average of 6.2 days after the start of treatment, in cows of group 1 - 7.4 day on average.

Example 2. To study the comparative effectiveness of the proposed tools have selected 36 cows, patients with purulent-catarrhal mastitis. Of animals, two groups were formed on the principle of steam. Cows in the control group was administered mastomatic, and the experimental group - the proposed tool.

Drugs were administered to the animals of both groups internatinale in the dose of 10 ml with an interval of 12 hours after milking to recovery. The results of studies of the comparative effectiveness of the proposed tools and matomela presented in table 2.

Table 2
Comparative effectiveness of the proposed tools and matomela.
GroupThe number of patientsThe number of daysRecovered
GoalssharestreatmentGoalsShares%
Control1832821832100
Experienced1839621839100

From table 2 it is seen that the experimental and the control group recovered all animals, but the duration of therapeutic course in the control was, on average, two days more.

Example 3. In parallel with the study of the comparative effectiveness of the proposed tools and matomela determined the dynamics of p is creased blood, body temperature in patients with animals. To do this in the morning took the blood from the jugular vein and measured body temperature in the rectum before treatment and on day 5 of treatment.

The results of the study are presented in tables 3, 4.

Table 3
Dynamics of temperature
GroupTemperature in degrees
Normabefore the treatment5 day treatment
Control37,540,538,0
Experienced37,5of 40.937,5

The temperature in the experimental animals on the first day of treatment was increased on average by 3C, and on day 5 of treatment was within the physiological norm (table 3), which indicates the favorable impact of the proposed funds for the animals.

/tr>
Table 4
Dynamics of blood
Blood countsNormaA group of cows
ControlExperienced
before the treatment5 daybefore the treatment5 day
Erythrocytes, mn5,0-7,5the 5.250,255,620,624,320,327,00,5
Hemoglobin, g/l99,0-129,060,02,1of 77.01,968,00,8100,00,8
Hematocrit, %35,0-45,024,01,832,11,1227,30,337,80,8
Leukocytes, thof 4.5 to 12.012,73,35,80,812,73,34,50,5
Lymphocytes, %40,0-65,070,0,9 67,21,0from 71.30,356,21,2
Monocytes, %2,0-7,011,30,24,70,29,60,63,80,8
Granulocytes, %28,0-58,043,41,435,20,232,10,128,20,2
Platelets, th260,0-700,0147,03,8220,05,0150,05,0of 270.05,0

In animals of the experimental and control groups quantitative indicators of most elements of blood were within physiological norms (table 4). The exception was leukocytes, lymphocytes, monocytes, granulocytes, whose content in cows in both groups were increased before treatment. Treatment of cows with mastitis using the proposed means positive influence on erythropoiesis, as the number of erythrocytes increased from an average of 2.68 million, while in the control group and 0.37 million, respectively, with indicators at the beginning of the experience. Animals of the experimental group the number of lymph is Titov blood before treatment was at a high level, and after treatment did not exceed the physiological norm.

Economic efficiency of treatment of cows with mastitis using the proposed funds amounted to 7.64 rubles per 1 ruble costs.

The treatment for clinical mastitis, including trivet, Cefotaxime, prednisolone, nystatin is in the following ratio:

trivet10.0 ml
Cefotaxime750 mg
prednisolone10.0 mg
nystatin325,0 ml



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, more specifically to new dosage forms of cephem compounds effective for treating bacterial infections.

EFFECT: dosage forms are stable; they show the improved solubility and are especially applicable for parenteral administration.

9 cl, 29 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary and is intended for treatment and prevention of postpartum acute mastitis in cows. Medication contains antimicrobial, anti-inflammatory preparations and distilled water. Medication additionally contains licorice root. As antimicrobial preparation it contains metronidazole. as anti-inflammatory preparation it contains ciprofloxacin, with the following component ratio, g/l: licorice root 80-85 g; metronidazole 3.5-4.0 g; ciprofloxacin 2.0-2.5 g; distilled water - the remaining part.

EFFECT: application of claimed medication provides expressed antimicrobial and anti-inflammatory effect with simultaneous reduction of organism's response to histamine, release of spasm of smooth muscles and reduction of permeability of capillaries.

4 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: method involves prescribing proton pump inhibitor with one antibiotic in a dual therapy and with two antibiotics with a triple therapy twice a day within the course of 7-10 days. Helicobacter is eradicated by the separate administration of drugs. The proton pump inhibitor (omeprazole or pantoprazole) is administered two hours before the antibiotic in the dual therapy and four hours before the second antibiotic in the triple therapy. The drugs are taken for the second time 12 hours after the first one. The antibiotics (clarithromycin, amoxicillin or fromilid) are taken with water 250ml.

EFFECT: invention enables providing the more effective eradication of Helicobacter by the exposure of total therapeutic bioavailability of each preparation with underlying permanent gastric alkaline environment.

2 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry and represents a cream for medical application for local treatment of bacterial infections and for wound healing, which contains fusidic acid in an amount of 0.1 wt % to 25 wt % and a biopolymer, preferentially chitosan; fusidic acid is formed in situ in an oxygen-free medium; the above cream contains fusidic acid formed in situ by transforming sodium fusidate at adding the acid slowly, with a particle size of an active agent of the substance of 2.33 mcm to 16.3 mcm, while the biopolymer is introduced into a cream base containing at least one ingredient of each type: primary and secondary emulsifying agents specified in a group containing ketostearyl alcohol, ketomacrogol-1000, polysorbate-80, Span-80, paraffin as a wax product, a combined solvent specified in a group containing propylene glycol, hexylene glycol, polyethylene glycol-400, nitric acid or lactic acid and water.

EFFECT: invention provides the high stability of the active ingredient during the whole shelf life.

12 cl, 18 tbl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology and represents a composition for inducing an immune response against Staphylococcus aureus (versions), a method for inducing the immune response against Staphylococcus aureus, and a method for eliciting passive immunity against Staphylococcus aureus in an individual. The composition contains an effective amount of the recovered capsular polysaccharide 5 S. aureus conjugated with the CRM197 carrier protein, an effective amount of the recovered capsular polysaccharide 8 S. aureus conjugated with the CRM197 carrier protein, and at least one ingredient specified in a group consisting of an effective amount of the recovered polypeptide of the clumping factor A (ClfA) of S. aureus, an effective amount of the recovered polypeptide of the clumping factor B (ClfB) of S. aureus (ClfB) and an effective amount of the recovered protein MntC of S. aureus. The capsular polysaccharide type 5 represents a capsular polysaccharide of high molecular weight from 70 to 300 kD. The capsular polysaccharide type 8 represents a capsular polysaccharide of high molecular weight from 70 to 300 kD, wherein from 5 to 23 lysines in CRM197 are conjugated. The CP5 and CP8 conjugates have the molecular weight from approximately 200 kD to approximately 5000 kD.

EFFECT: presented invention enables eliciting the improved immune response against Staphylococcus aureus.

25 cl, 29 dwg, 26 tbl, 32 ex

FIELD: medicine.

SUBSTANCE: method involves immunising with 5107 microbial cells Vibrio cholerae 5879; 10 days later, a common pool of anticholeraic Ig is recovered from enteric washing liquid. That is combined with producing the primary enterocyte culture from intact mice. Thereafter, the doubly-diluted anticholeraic Ig are applied in an amount of 3 ml on a monolayer of erythrocytes formed in wells of culture panels. The latter are added with alive choleraic vibrions of the strain Vibrio cholerae 5879, 40 m.c. per 1 erythrocyte and incubated for 3 hours. Then, the panels are washed three times, fixed with ethanol for 20 minutes and stained by Romanowsky-Giemsa. Local humoral anticholeraic immunity is assessed under the microscope by the number of vibrions stained in dark blue and attached to one erythrocyte.

EFFECT: method enables assessing specific local humoral immunity and intensifying the anti-adhesive activity of the common pool of anticholeraic immunoglobulin.

4 cl, 2 ex, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new bacitracin compounds with antibiotic activity

,

wherein at least one of R1, R2 and R3 represents -CH=CH2 and wherein R1, R2 and R3 independently represent -H, -CH3 or -CH=CH2.

EFFECT: preparing the new bacitracin compounds.

13 cl, 8 dwg, 7 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new compounds of formula I and their pharmaceutically acceptable salts, method for preparing them by the fermentation of a microorganism of the species Streptomyces (PM0626271/MTCC 5447), and to their pharmaceutical compositions containing one or more compounds of formula I as an active ingredient.

EFFECT: compounds of formula I are used for treating and preventing the diseases caused by bacterial infections.

4 cl, 3 dwg, 6 tbl, 9 ex

FIELD: biotechnologies.

SUBSTANCE: invention represents a producing method of cream containing fusidic acid, which involves a stage of application of sodium fusidate as an initial active ingredient and conversion of the above sodium fusidate in situ to fusidic acid in an oxygen-free medium by immediate addition of the acid to a cream base containing a preservative, an acid, a cosolvent, an emulsifier, a wax-like product and water.

EFFECT: obtaining cream having high stability at storage and smaller particles of an active ingredient.

9 cl, 11 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and represents dermatological cream, intended for local treatment of bacterial skin infections and for healing wounds associated with them, which contains framycetin sulfate and biopolymer, included into cream base, which contains at least one substance from each of the following groups: preservative, primary and secondary emulsifier, selected from the group which contains ketostearyl alcohol, ketomacrogol 1000, polysorbate-80 and Span-80; paraffin as wax-like product, cosolvent, selected from the group, including propylene glycol, hexylene glycol and polyethylene glycol-400; nitric acid or lactic acid and water, with said biopolymer preferably being chitosan.

EFFECT: invention provides higher therapeutic effect.

8 cl, 10 tbl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, more specifically to new dosage forms of cephem compounds effective for treating bacterial infections.

EFFECT: dosage forms are stable; they show the improved solubility and are especially applicable for parenteral administration.

9 cl, 29 tbl, 8 ex

FIELD: chemistry.

SUBSTANCE: invention represents method of obtaining alimemazine tartrate solution for introduction by injection, characterised by the fact that sodium sulfate and ascorbic acid are dissolved with constant mixing in water for injections, which has temperature 20-25C and was preliminarily bubbled with carbon dioxide for 15-25 minutes, after complete dissolution alimemazine tartrate is introduced and mixed for 10-20 minutes, filtered by method of sterilising membrane filtration, obtained solution is packed into dimming glass ampoule with application of gas protection by carbon dioxide with further sterilisation of solution at temperature 100-105C for 30 minutes.

EFFECT: method improvement.

2 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a concentrated acidic component for producing a hemodialysis solution. The acidic component contains the following ingredients in an amount of producing 1 litre of the solution in water purified for hemodialysis: 204.7-215.0 g of sodium chloride NaCl, 6.2-9.0 g of calcium chloride CaCl2*2H2O, 3.56-7.12 g of magnesium chloride MgCl2*6H2O, 5.22-10.44 g of potassium chloride KCl, 0.021-6.28 g of acetic acid and 0.02-6.2 g of succinic acid. Also, the invention refers to the hemodialysis solution containing the above concentrated acidic component, water purified for hemodialysis, and bicarbonate component. The invention also refers to a method for producing the hemodialysis solution with the method involving supplying the concentrated acidic component into a hemodialysis apparatus, diluting with water purified for hemodialysis, and mixing with bicarbonate component. What is also declared is a kit for producing the concentrated acidic component containing sodium chloride, calcium chloride, magnesium chloride, potassium chloride, succinic acid in the form of dry agents and acetic acid in the form of a liquid agent.

EFFECT: invention provides higher effectiveness by a biochemical compatibility with blood plasma of the hemodialysis solution.

36 cl, 18 tbl, 16 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, namely ophthalmology, and aims at treating cataract. A drug preparation for treating cataract based on the active substance sodium dihydroazapentacene polysulphonate (azapentacene) is presented in the form of ophthalmic drops. Stabilising is ensured by using a borate buffer and potassium chloride, a borate buffer and sodium chloride, a phosphate buffer, a quaternary ammonium derivative, Nipaging and a preserving agent of mercury derivatives. The ingredients are used in the declared amounts.

EFFECT: using the group of inventions provides the enhanced antimicrobial properties and the reduced toxicity of the ophthalmic drops, thereby increasing the clinical effectiveness in cataract.

6 cl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to a new pharmaceutical composition in the form of spray for oral administration, containing an aqueous solution of sildenafil citrate as an active substance in the amount of 3-30 wt %. The composition contains stabilising agents in the form of pharmaceutically acceptable calcium salts taken in an amount required to reduce pH to 3.0 to 6.0. The calcium salts are specified in a group consisting of calcium lactate pentahydrate, calcium lactate trihydrate, calcium gluconate, calcium malate, calcium glycolate, calcium chloride hexahydrate and calcium chloride dihydrate. What is also described is a method for preparing the composition by introducing the pharmaceutically acceptable calcium salts as the stabilising agents into the aqueous solution of sildenafil citrate.

EFFECT: pharmaceutical composition in the form of oral spray is free from organic solvents and applicably for sexual dysfunction.

13 cl, 8 ex

FIELD: chemistry.

SUBSTANCE: invention represents pharmaceutical composition for correction and therapy of manifestations of amyloid intoxication in patients with brain pathologies, which are characterised by the fact that it contains melatonin 3-10 mg and memantine 5-300 mg.

EFFECT: effective treatment of patients, including cases of moderate cognitive disorders.

4 cl, 2 ex, 6 tbl, 7 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a topical composition containing a combination of natural salt or pure sodium chloride and glucose mixed in ratio 1:1-30 (wt/wt) as an active ingredient in an amount effective for treating bacterial vaginosis caused by Cardnerella vaginalis together with a pharmaceutically acceptable carrier.

EFFECT: invention provides the higher pharmacological activity.

4 cl, 4 ex, 5 tbl

FIELD: medicine.

SUBSTANCE: as active ingredients, a formulation contains fenoterol hydrobromide and ipratropium bromide monohydrate; the excipients are absolute ethanol, triethylcitrate, propellant 1,1,1,4 tetrafluoroethane (HFA-134a) and/or 1,1,1,2,3,3,3-heptafluoropropane (HFA-227ea) and a pharmaceutically acceptable acid specified in hydrochloric, orthophosphoric and citric acids.

EFFECT: increasing the respirable fraction and obtaining an optimised particle release profile.

2 dwg, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics and represents method of treating prostate cancer, which includes introduction to patient of composition, which contains degarelix lyophilisate or its pharmaceutically acceptable salt and excipient, dissolved in solvent, in initial dose 200-300 mg of degarelix in concentration 20-80 mg of degarelix per ml of solvent with the following after 14-56 days after initial dose supporting dose 320-55 mg of degarelix in concentration 50-80 mg of degarelix per ml of solvent, possibly with one or more than one following additional supporting dose 320-550 mg of degarelix in concentration 50-80 mg of degarelix per ml of solvent, introduced with interval from 56 days to 112 days between each supporting dose.

EFFECT: invention provides long release of degarelix from obtained depot of medication without increase of occurrence of side effects.

11 cl, 1 ex, 2 dwg, 4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and represents a gel biologically active composition for topical application containing chitosan hydrochloride in an amount of 10-20 wt %, an organic acid in an amount of 1-10 wt %, distilled water - the rest. The above organic acid is specified in acetic, ascorbic, glycolic, lactic, citric or succinic acids.

EFFECT: providing a lower toxicity and a wider spectrum of biological action of the composition ensured by the synergetic effect of a reaction of chitosan hydrochloride and the organic acid.

11 ex, 11 tbl, 2 dwg

FIELD: medicine.

SUBSTANCE: method involves prescribing proton pump inhibitor with one antibiotic in a dual therapy and with two antibiotics with a triple therapy twice a day within the course of 7-10 days. Helicobacter is eradicated by the separate administration of drugs. The proton pump inhibitor (omeprazole or pantoprazole) is administered two hours before the antibiotic in the dual therapy and four hours before the second antibiotic in the triple therapy. The drugs are taken for the second time 12 hours after the first one. The antibiotics (clarithromycin, amoxicillin or fromilid) are taken with water 250ml.

EFFECT: invention enables providing the more effective eradication of Helicobacter by the exposure of total therapeutic bioavailability of each preparation with underlying permanent gastric alkaline environment.

2 cl, 3 ex

Up!